Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

42.71USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$42.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,040
52-wk High
$45.73
52-wk Low
$22.18

Chart for

About

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets:... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $815.35
Shares Outstanding(Mil.): 19.09
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

* Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

Sep 13 2017

BRIEF-Enanta pharmaceuticals Q3 loss per share $0.44

* Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017

Aug 07 2017

BRIEF-Enanta Pharmaceuticals announces new data on EDP-938

* Phase 1 clinical study for RSV expected to begin in fourth calendar quarter of 2017

Jun 26 2017

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

Jun 23 2017

BRIEF-Enanta Pharmaceuticals reports Q2 loss per share $0.28

* Enanta Pharmaceuticals reports financial results for its fiscal second quarter ended March 31, 2017

May 08 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

Apr 21 2017

Earnings vs. Estimates